Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$79.29 USD

79.29
1,037,884

-1.20 (-1.49%)

Updated Nov 7, 2024 03:59 PM ET

After-Market: $79.32 +0.03 (0.04%) 7:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Hologic Q4 Earnings Lag, Revenues Top, Stock Down in Aftermarket

by Zacks Equity Research

HOLX's fiscal 2024 fourth-quarter results underscore the durable growth of its businesses.

Hologic (HOLX) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Hologic (HOLX) Q4 Earnings Miss Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of -0.98% and 0.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Unlocking Q4 Potential of Hologic (HOLX): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Hologic (HOLX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Hologic (HOLX) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

In the latest trading session, Hologic (HOLX) closed at $80.46, marking a -0.46% move from the previous day.

Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Non-COVID-19 Diagnostics Sales Drive Hologic's Q4 Earnings?

by Zacks Equity Research

HOLX's fiscal 2024 fourth-quarter results are expected to reflect a solid performance of the Diagnostics business, led by the base Molecular franchise.

Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Hologic (HOLX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

The latest trading day saw Hologic (HOLX) settling at $81.15, representing a -0.51% change from its previous close.

Moumi Mondal headshot

Should You Buy, Sell or Hold HOLX Stock Ahead of Q4 Earnings?

by Moumi Mondal

Hologic's upcoming fourth-quarter fiscal 2024 financial report is expected to reflect strength in core franchises.

Hologic (HOLX) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Hologic (HOLX) stood at $81.66, denoting a +0.05% change from the preceding trading day.

HOLX Launches BustTheMyth Campaign for Breast Health Awareness

by Zacks Equity Research

Hologic enters Breast Cancer Awareness Month with the launch of the BustTheMyth campaign. This campaign is aimed at busting myths regarding breast health.

QIAGEN's TB Testing Business Gets New Exposure at Global Summit

by Zacks Equity Research

QGEN distributes over 125 million QuantiFERON-TB tests across more than 130 countries worldwide, significantly contributing to national TB control strategies.

Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

GEHC's MIM Software to Aid Radiation Therapy With Its Latest FDA Nod

by Zacks Equity Research

GE Healthcare's MIM Software announces the FDA clearance of Monte Carlo Dosimetry for Theranostics, enhancing precision in personalized treatment plans.

Will Hologic (HOLX) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Moumi Mondal headshot

Should You Bet on HOLX Stock This Breast Cancer Awareness Month?

by Moumi Mondal

Hologic has kicked off the annual breast cancer awareness month with a new campaign. But how well is the stock doing now?

Hologic (HOLX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

Hologic (HOLX) closed at $80.26 in the latest trading session, marking a +0.48% move from the prior day.

Hologic (HOLX) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

Hologic (HOLX) reachead $79.77 at the closing of the latest trading day, reflecting a -0.98% change compared to its last close.

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

HOLX Stock Gains From New Offerings Despite Macro Issues

by Zacks Equity Research

In Breast Health, Hologic expands its product offering from imaging to cover the continuum of breast cancer care, including biopsy and surgery.

Is HOLX Stock a Smart Hold for Your Portfolio Right Now?

by Zacks Equity Research

Hologic's strength in Molecular Diagnostics is highly promising. Yet, macroeconomic uncertainties can pose headwinds for its operations.